Company intelligence / Profile preview

TO Pharma

Vienna, Vienna, Austria

Ownership: Private
Employees: ~20
Development stage: Other

Overview

TO Pharma is an Austrian specialty pharmaceutical company dedicated to the development, production, and distribution of cannabinoid-based medicinal products. The company is a leading provider of pharmaceutical-grade Dronabinol and Cannabidiol (CBD) in the European market, adhering to strict Good Manufacturing Practice (GMP) standards. Their portfolio is designed to address unmet medical needs in areas such as chronic pain management, oncology, and neurology. By focusing on standardized, high-purity extracts and synthetic cannabinoids, TO Pharma provides clinicians and pharmacists with reliable therapeutic options for complex conditions.

Therapeutic areas: PsychiatryNeurologyOncologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on TO Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TO Pharma.

Explore the full profile